You are here

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study

 

Online download statistics by month:

Online download statistics by month: April 2022 to November 2024

AbstractFullPdf
Apr 2022564583248
May 2022415425172
Jun 202219820473
Jul 202213814842
Aug 202215015040
Sep 202221922155
Oct 202218819256
Nov 202213213236
Dec 202212712840
Jan 202311811932
Feb 2023929334
Mar 2023919238
Apr 2023808031
May 2023959529
Jun 2023959624
Jul 2023656721
Aug 2023929315
Sep 2023868616
Oct 2023838324
Nov 20239710018
Dec 2023848532
Jan 2024464735
Feb 2024545523
Mar 2024858595
Apr 2024616132
May 2024575824
Jun 2024626133
Jul 2024737428
Aug 2024505119
Sep 2024484827
Oct 2024606026
Nov 2024676822
Total387239401440